Co-Diroton

Quick links to important sections

Co-Diroton

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Co-Diroton

Quick Facts

Property Description
Active ingredients Lisinopril and Hydrochlorothiazide (HCTZ)
Form Tablets (Fixed-Dose Combination, FDC)
Pharmacological Class Antihypertensive Agents (ACE inhibitor + Diuretic)
Common Use Management of high blood pressure (Essential Hypertension)
Origin Synthetic

What Type of Medicine is Co-Diroton?

Co-Diroton is a prescription-only medicine for oral administration in the form of tablets, categorized as an antihypertensive agent. It is defined as a synthetic fixed-dose combination (FDC) product, meaning it contains two separate active ingredients in a single preparation. This FDC approach is clinically recognized for enhancing patient adherence and is a strategy utilized in the management of essential hypertension in adults. Other popular brands sharing this exact formulation include Zestoretic and Prinzide, confirming the established utility of this specific dual mechanism.


What is Co-Diroton Composed Of?

The core composition of Co-Diroton includes the two chemical substances: Lisinopril and Hydrochlorothiazide (HCTZ), alongside standard solid excipients. Lisinopril functions as an Angiotensin-converting enzyme (ACE) inhibitor, which targets hormonal pathways that regulate blood vessel constriction, while Hydrochlorothiazide is a thiazide diuretic. The co-administration of these two agents in a single tablet provides a comprehensive pharmacological profile targeting different pathways of blood pressure regulation.


What is the Primary Purpose of Co-Diroton?

The primary purpose of Co-Diroton is to provide foundational antihypertensive therapy by effectively treating chronic high blood pressure in adults who require combination therapy. The combination of agents provides a synergistic effect by addressing both vascular constriction and excess fluid volume. This dual therapeutic action enables sustained control of blood pressure, a key requirement for managing the underlying cardiovascular condition.

Regulatory References

  1. Lisinopril and Hydrochlorothiazide: MedlinePlus Drug Information

What side effects are possible with Co-Diroton?

Possible Side Effects and Safety Information

This section outlines the officially documented safety profile of Co-Diroton (Lisinopril/Hydrochlorothiazide) as derived from government regulatory labeling. It is not a guide for use or medical advice.


Adverse Reaction Classification

Adverse reactions are organized by the System-Organ Class (SOC) and their reported frequency in clinical studies:

  • Common Reactions (affecting up to 1 in 10 people): Dizziness, Headache, and persistent Cough are frequently documented. Other common events include fatigue and orthostatic effects (dizziness upon standing).
  • System-Organ Classes Involved: Side effects are documented across various body systems, including the Nervous System, Respiratory System, Gastrointestinal System, and disorders related to Metabolism and Nutrition (e.g., electrolyte imbalance).

Serious Adverse Reactions and Restrictions

Regulatory documents highlight specific serious and rare events, alongside mandatory safety restrictions:

Safety Entity Description
Serious Adverse Reactions Angioedema (swelling of the face, throat, or tongue) is a key risk requiring immediate medical attention. Acute Renal Failure and Hepatic Failure are also documented, although rarely.
Contraindications The medication must not be used in patients with a history of angioedema related to any ACE inhibitor, those with Anuria (no urine production), or during Pregnancy due to the risk of fetal injury and death.

Safety Monitoring and Patterns

Official labeling mandates the periodic monitoring of serum electrolytes and renal function due to the risk of imbalance and dysfunction. Orthostatic Hypotension is noted as being more common upon initiating or increasing the dosage. The risk of Non-melanoma Skin Cancer is documented as increasing with the cumulative dose of the Hydrochlorothiazide component over long-term exposure.

Overdose and Emergency Response

The official regulatory profile for Co-Diroton overdose emphasizes the risk of severe physiological instability arising from the combined effects of Lisinopril and Hydrochlorothiazide. The most commonly documented presentation is profound hypotension (a severe drop in blood pressure), which may rapidly progress to circulatory shock, a life-threatening event. Other key manifestations include significant electrolyte disturbances, such as hyponatraemia and hypokalaemia, alongside changes in heart rate (tachycardia or bradycardia) and general signs of fluid loss like dizziness and lethargy. Acute renal failure is also a documented, severe outcome.

Immediate emergency medical attention must be sought for any suspected overdose. The mandatory action required by government labeling is to contact emergency services or a Poison Help line immediately due to the risk of life-threatening complications. Management is strictly symptomatic and supportive, as no specific antidote is known for this combination. Supportive measures described in regulatory documents include restoring fluid volume through an intravenous infusion of normal saline solution and positioning the patient in the shock position. For refractory cases, the use of intravenous catecholamines may be considered. Continuous medical supervision is necessary to monitor vital signs, serum electrolytes, and renal function.

Therapeutic Uses of Co-Diroton

What Co-Diroton Treats: Main Uses and Benefits

Co-Diroton, the fixed-dose combination of lisinopril and hydrochlorothiazide (HCTZ), may be part of symptomatic management for hypertension (high blood pressure). This combination is applied in addressing high blood pressure, particularly in conditions where functional stability becomes affected by prolonged physiological strain.

This medication is generally used for managing symptom clusters that may become intense or disruptive, especially when dealing with symptoms related to heightened physiological activity and systemic imbalance. Its use is relevant when supportive symptom management is appropriate, such as in clinical settings that involve acute or unstable symptom patterns. Lisinopril-HCTZ is relevant for easing symptoms linked to organ-specific functional stress. The combination generally assists with maintaining functional stability and contributes to easing the overall symptom load.

The medication is commonly used to help with the management of essential hypertension, which is a condition characterized by periods of heightened symptoms. By easing the overall systemic burden, the treatment provides supportive relief that helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.


Quick Fact: Relief for Symptoms that Create Noticeable Physiological Strain


Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Co-Diroton?

The regulatory profile for Co-Diroton (lisinopril/hydrochlorothiazide) establishes its use primarily in adults with essential hypertension. Official documentation defines strict rules regarding who is ineligible to use this medicine.

Absolute Contraindications

Use is strictly contraindicated for patients who exhibit hypersensitivity to any component, including lisinopril, hydrochlorothiazide, other ACE inhibitors, or sulfonamide-derived drugs. It is prohibited for patients with Anuria (absence of urine formation) or a history of angioedema (hereditary, idiopathic, or linked to prior ACE inhibitor therapy). The medicine is contraindicated during the second and third trimesters of pregnancy. Regulatory warnings also prohibit its use with aliskiren in diabetic patients and with sacubitril-containing medicines within 36 hours.

Population Restrictions

Use is officially not recommended for the pediatric population as safety and efficacy have not been established in children. Furthermore, it is not recommended for patients with severe renal impairment (creatinine clearance less than 30 mL/min) and for women who are breastfeeding. Special caution is advised for the geriatric population and patients with impaired hepatic function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with other substances as officially documented in regulatory prescribing information for Lisinopril/Hydrochlorothiazide (Co-Diroton).


Official Interaction Statements

Classification Interacting Substance(s) Documented Outcome (Regulatory Description)
Contraindicated Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) Prohibited due to a documented increase in the risk of angioedema (severe swelling).
Contraindicated Aliskiren Prohibited in diabetic patients due to documented heightened risks of renal impairment, hypotension, and hyperkalemia (high potassium levels).
Timing-Required Neprilysin Inhibitors Requires a mandatory 36-hour separation period when switching to or from co-administration.

Clinically Significant Interactions

Co-administration with Lithium may result in a documented increase in serum lithium concentrations and risk of toxicity. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause a loss of antihypertensive effect and increase the risk of renal function deterioration. Other Diuretics, Potassium Supplements, or Potassium-Sparing Diuretics increase the documented risk of hyperkalemia or excessive reduction in blood pressure. The systemic exposure of both active ingredients is documented as increased in elderly patients, representing a population-dependent pharmacokinetic alteration. The drug's absorption is not influenced by food, and it is not subject to CYP-mediated drug interactions.

Mechanism of Action

Co-Diroton is a fixed-dose combination containing the angiotensin-converting enzyme (ACE) inhibitor lisinopril and the thiazide diuretic hydrochlorothiazide. .

Lisinopril is a competitive inhibitor of the ACE enzyme, primarily found on endothelial cell surfaces. This interaction blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor and stimulator of aldosterone release. The resulting reduction in angiotensin II levels promotes vasodilation in arterioles, directly reducing systemic vascular resistance. Furthermore, suppressed aldosterone secretion diminishes sodium and water reabsorption in the renal collecting ducts, increasing natriuresis and fluid excretion.

Hydrochlorothiazide acts by binding to and inhibiting the sodium chloride cotransporter (NCC) located on the apical membrane of the renal distal convoluted tubules. This antagonism prevents the reabsorption of sodium and chloride ions from the tubular lumen, which, in turn, increases the delivery of sodium and water to the collecting duct. This initial action induces diuresis and subsequently lowers total plasma volume. The combined, complementary actions of both agents on vascular tone and fluid dynamics modulate system-level circulatory resistance and volume.

Dosage and Administration Information

How to Use Co-Diroton

Co-Diroton is an oral, fixed-dose combination (FDC) tablet of lisinopril and hydrochlorothiazide (HCTZ) prescribed for long-term management of essential hypertension. The medication is taken once daily at approximately the same time each day, and may be administered with or without food.

Official Dosing and Administration Principles

Instruction Domain Official Requirement (Label-Based)
Route & Frequency Oral, once daily, usually taken in the morning to manage the HCTZ component.
Dosing Regimens The FDC is not indicated for initial therapy; it is used to replace the separate components once the patient has been stabilized on corresponding doses. Standard maintenance doses range from 10 mg/12.5 mg to 20 mg/25 mg lisinopril/HCTZ daily.
Titration Pattern Dose adjustments, if needed, should be made after intervals of 2 to 3 weeks to fully assess the blood pressure response. The maximum recommended dose is typically 80 mg lisinopril / 50 mg HCTZ per day.
Special Conditions Diuretic therapy, if previously used, should generally be discontinued for 2–3 days prior to initiation of the FDC to minimize the risk of sudden blood pressure reduction. Use is not authorized for patients with severe renal impairment (creatinine clearance <30 mL/ min).
Population Use Safety and effectiveness have not been established in the pediatric population.

These instructions define the standardized, label-based approach for the correct use of Co-Diroton. The FDC must only be introduced as a substitution for the established free components, a procedural requirement that strictly governs its application in clinical practice.

Recent Clinical Evidence

Recent Clinical Evidence: Co-Diroton


Study Design and Focus

Research investigating the fixed-dose combination of Lisinopril (an ACE inhibitor) and Hydrochlorothiazide (a diuretic) has focused on its potential role in managing hypertension (high blood pressure). The research design included studies on how the combination of the two components was hypothesized to interact to influence blood pressure regulation. These investigations evaluated whether the fixed-dose approach resulted in a change in blood pressure metrics, particularly in patients with primary (essential) hypertension.

Phase III Clinical Trial Data

A key Phase III study reported that the combination was associated with changes reported in systolic and diastolic blood pressure levels in the studied patient population. The trial generally involved patients who had not achieved adequate blood pressure control with monotherapy (a single agent) alone. These studies typically span an eight-to-twelve-week duration to assess the sustained effects of the regimen.

Metric Assessed Key Finding Reported
Systolic BP Associated with mean changes from baseline.
Diastolic BP Associated with mean changes from baseline.

Data collected across different demographics, including age and ethnicity, were evaluated to see if the treatment was associated with similar results across these patient groups. The highest metric values in the study were frequently reported in the subset of patients who completed the 12-week study duration, consistent with the expected timeline for assessing sustained antihypertensive efficacy.

Further Research Directions

Ongoing and future research continues to investigate the long-term effects of this drug combination on cardiovascular outcomes and to refine patient selection criteria. These findings require additional, larger-scale studies to fully evaluate any potential associations between long-term use and major cardiac events.

Frequently Asked Questions (FAQ)

Common questions about Co-Diroton (FAQ)


Q: Is Co-Diroton considered a 'water pill' because of the hydrochlorothiazide component?

Yes, the medicine contains a diuretic, which is often called a 'water pill.'

The hydrochlorothiazide component is officially classified as a thiazide diuretic. This type of medicine works by prompting the kidneys to excrete more sodium and water, reducing overall fluid volume in the body.


Q: What is the significance of the two numbers in the drug's strength (e.g., 10/12.5)?

The two numbers represent the amount of each active ingredient in the tablet.

The first number indicates the dose of the lisinopril component. The second number indicates the dose of the hydrochlorothiazide component in the fixed-dose combination tablet.


Q: How long does it typically take to see the effects of Co-Diroton?

The time it takes to see the effects of this medication varies.

The initial blood pressure reduction from the lisinopril component can begin in about one hour and often reaches its peak in six hours. However, official information notes that achieving the full, intended blood pressure control may require continuous use for two to four weeks.


Q: Is it normal to feel a mild cough when starting Co-Diroton?

A persistent cough is documented as a common adverse reaction.

Official documents classify persistent cough as a common side effect of the lisinopril component, affecting up to 1 in 10 individuals in clinical studies.


Q: Can Co-Diroton interact with over-the-counter pain relievers like ibuprofen?

The medicine has a documented interaction with a class of pain relievers called NSAIDs.

This includes common over-the-counter pain relievers. Official warnings note that using the medication with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) may cause a loss of the blood pressure-lowering effect and increase the risk of kidney function deterioration.


Q: Are there any common foods or drinks that should be avoided while using Co-Diroton?

Official guidance advises caution regarding potassium intake.

Regulatory documents caution against consuming foods high in potassium or using potassium supplements and salt substitutes. This is because the medication can affect the balance of potassium in the bloodstream.


Q: Can Co-Diroton be used by older adults?

The medicine is authorized for use in adults, which includes the older population.

Regulatory documents do note that older patients may show higher levels of the lisinopril component in their blood. Special caution is often advised for the geriatric population.


Q: What are the concerns about using Co-Diroton in hot weather?

Official warnings are documented regarding dehydration.

Individuals using this drug may become easily dehydrated due to the diuretic component. Regulatory information cautions against becoming overheated in hot weather, as severe dehydration may be associated with very low blood pressure or kidney issues.


Q: Does Co-Diroton cause changes in potassium levels?

Yes, regulatory documents indicate that the medicine can affect potassium levels.

The lisinopril component may increase potassium, while the hydrochlorothiazide component tends to decrease it. Clinical studies examining the fixed combination generally showed a small mean decrease in potassium levels.


Q: Is there any research that looks at long-term use of Co-Diroton?

Studies have examined the use of the medicine for long periods.

The blood pressure-lowering effects of the lisinopril component have been documented to be sustained during long-term therapy. Research continues to investigate the long-term effects of the combination on overall cardiovascular health metrics.


Q: Is Co-Diroton known to affect kidney function over time?

Yes, official documents state that kidney function should be monitored.

The medication is not authorized for use in individuals with severe kidney impairment. Regulatory warnings document rare instances of serious kidney problems and underscore the need for periodic monitoring of kidney function during treatment.


Q: Why is lisinopril combined with hydrochlorothiazide in this drug?

The combination of ingredients is intended to achieve a dual action.

Official labeling states the components target two different pathways for blood pressure regulation. The lisinopril component is specifically documented to counteract the loss of potassium that is often associated with the diuretic action of hydrochlorothiazide.


Q: Do people using Co-Diroton usually notice feeling dizzy when they stand up?

Yes, feeling dizzy when standing up is a commonly documented event.

This effect, known as orthostatic effects, was reported in up to 3% of individuals in clinical trials. Official information notes that this may be more common when an individual first starts using the medication or when the dosage is changed.


Q: Can Co-Diroton be taken at the same time as other heart medications?

The drug's official labeling contains specific prohibitions.

Regulatory documents strictly prohibit the use of this medicine with certain other heart or blood pressure medications, particularly those that also block the Renin-Angiotensin System. Specific guidance is required for co-administration with any other prescribed medicine.


Q: Is Co-Diroton safe for individuals with diabetes?

Official documents state a restriction for diabetic patients regarding a specific combination.

Use is strictly prohibited if an individual with diabetes is also using the medicine Aliskiren. However, official labeling generally notes the importance of managing blood pressure in patient populations, including those with diabetes.


Q: Does Co-Diroton interact with supplements like magnesium or calcium?

The medicine is associated with changes in electrolyte balance.

The hydrochlorothiazide component is a thiazide diuretic, which regulatory documents state is associated with the loss of several electrolytes, including magnesium.


Q: Is Co-Diroton used for any conditions other than high blood pressure?

The medicine is authorized for one primary use by regulatory agencies.

The fixed-dose combination product is officially indicated for the treatment of essential hypertension (high blood pressure) in adults. Regulatory documents do not contain information on off-label uses.


Q: Is it true that Co-Diroton can increase sensitivity to the sun?

Official warnings exist regarding sun exposure.

The hydrochlorothiazide component is associated with an increased risk of non-melanoma skin cancer with long-term exposure. Official documentation suggests precautions regarding sun exposure while using this type of medication.


Q: Can stopping Co-Diroton suddenly cause any issues?

Abrupt discontinuation of the lisinopril component has not been linked to a rapid blood pressure increase.

Regulatory information states that stopping the lisinopril component suddenly has not been documented as causing a significant overshoot in blood pressure. Changes to a treatment plan must be discussed with a qualified healthcare professional.


Q: Does Co-Diroton have a weight-gain side effect that is commonly reported?

Clinical studies on the lisinopril component generally do not report measurable weight gain.

Official documents indicate the drug is not associated with weight gain or loss. However, regulatory warnings note that unexpected or rapid weight gain could be a symptom of a serious, documented adverse reaction.


Q: Is Co-Diroton considered to be a 'first-line' treatment option?

The medicine is not typically used for initial treatment.

Official documents state the fixed-dose combination product is not indicated for use as initial therapy for high blood pressure. It is generally intended for individuals whose blood pressure has not been adequately controlled by taking a single medicine.


Q: Are there specific times of day Co-Diroton is recommended to be used?

Official instructions usually recommend taking the medicine once daily in the morning.

This advice is provided to help manage the diuretic component (hydrochlorothiazide). The medicine can be taken with or without food.


Q: Does using alcohol with Co-Diroton create any known concerns?

Yes, official documents note a potential additive effect with alcohol.

Regulatory information states that alcohol and the hydrochlorothiazide component may cause an additional lowering of blood pressure. This effect may increase the possibility of feeling dizzy or faint.


Q: Is the onset of action of Co-Diroton faster than taking the two medicines separately?

The combination tablet is officially documented as bioequivalent to taking the two medicines separately.

This means the two approaches are expected to result in the same levels of the active ingredients in the blood. Regulatory documents do not indicate the combination is faster acting than the separate components.


Q: What does the research say about Co-Diroton use in people with kidney artery issues?

Studies have examined the use of the lisinopril component in people with certain kidney artery issues.

Specifically, research has looked at the use of the lisinopril component in patients with renovascular hypertension, a form of high blood pressure related to kidney artery problems.


Q: Can Co-Diroton interact with mood stabilizers or psychiatric medications?

Yes, regulatory documents list an interaction with the medicine Lithium.

Official labeling documents a clinically significant interaction that may increase the concentration of Lithium in the bloodstream. This may increase the risk of toxicity.


Q: Is Co-Diroton widely available in different generic formulations?

Official labeling confirms that products containing the fixed-dose combination are available in generic formulations.

This means the drug is widely available under various non-branded names.


Q: Are there particular ethnic groups for whom Co-Diroton is described differently in terms of effectiveness?

Clinical trial data indicated some differences in effectiveness across patient populations.

Regulatory documents noted that the combination product appeared somewhat less effective in Black patients compared to other studied groups.


Q: Can Co-Diroton affect athletic performance or fluid balance?

Yes, the medicine is documented to affect fluid and electrolyte balance.

The diuretic component is associated with changes in the balance of fluid and electrolytes. Official documentation highlights the need to avoid dehydration, especially during physical activity.


Q: What is the typical duration of effect for a single dose of Co-Diroton?

The overall blood pressure lowering effect is sustained throughout the day.

The antihypertensive effect is documented to be maintained for at least 24 hours after a single dose. The diuretic component's action on fluid balance is generally shorter, lasting between 6 and 12 hours.


Q: Can Co-Diroton be used in people who are currently using dialysis?

The fixed-dose combination product is not authorized for use in individuals with severe kidney impairment.

Regulatory documents state that the medicine is not recommended for individuals with a creatinine clearance less than 30 mL/min.


Q: Is there any information on how Co-Diroton may affect blood sugar?

Yes, official documents indicate that blood sugar is a factor for consideration.

Regulatory warnings specify that use is prohibited when co-administered with Aliskiren in individuals with diabetes. Blood sugar levels are a common factor for monitoring during therapy involving thiazide diuretics.


Q: Does Co-Diroton require a special diet or fluid intake changes?

Yes, official documents contain cautions about diet and fluid intake.

Caution is advised regarding potassium-rich foods, potassium supplements, and salt substitutes. Official advice notes that liquid intake may need careful management due to the diuretic component's effect on fluid volume, especially in hot conditions.


Q: Are there any reported instances of Co-Diroton causing vision changes?

Official warnings document rare instances of vision-related reactions.

Regulatory warnings specifically document that the hydrochlorothiazide component can rarely cause an idiosyncratic reaction. This may result in a sudden onset of decreased visual acuity (nearsightedness) or ocular pain (acute angle-closure glaucoma).


Q: Do regulatory agencies specify a maximum duration for Co-Diroton use?

Regulatory documents do not specify a maximum duration of use.

Since the medicine is intended for the long-term management of chronic high blood pressure, official documentation does not set a maximum period for use.


Q: Why do official documents caution against using Co-Diroton with certain salt substitutes?

Official documents caution against co-administration with potassium.

Many salt substitutes contain potassium chloride, and regulatory documents warn against taking potassium supplements. This is because the combination may increase the risk of hyperkalemia (high potassium levels).

How should Co-Diroton be stored and disposed of?

Storage and Disposal Requirements

Co-Diroton (lisinopril/hydrochlorothiazide) must be stored under specific environmental constraints to preserve its stability, as outlined in official regulatory labeling.

Storage Scope Labeled Requirement
Temperature Range Store at controlled room temperature between 15°C and 30°C (59°F and 86°F).
Environmental Protection Must be protected from light and moisture.
Handling Constraints Keep the medicine from freezing.
Container Rule Store in a closed container.
Child Safety Keep out of the reach of children.

For disposal, do not keep outdated or no longer needed medication. Official instructions require you to ask your healthcare professional how you should dispose of any medicine you do not use. This ensures pharmaceutical waste is handled properly and prevents environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Co-Diroton found in:

A-Z Index: